Publication | Open Access
Paclitaxel-Conjugated PAMAM Dendrimers Adversely Affect Microtubule Structure through Two Independent Modes of Action
54
Citations
41
References
2013
Year
EngineeringCytoskeletonHydrophilic Paclitaxel-conjugated PolyamidoaminePaclitaxel-conjugated Pamam DendrimersConjugated PaclitaxelIndependent ModesTumor BiologyNanomedicineAnti-cancer AgentMolecular ImagingBiophysicsTumor TargetingPharmacologyCell BiologyTumor MicroenvironmentDrug TargetingPolymer-drug ConjugateNano-drug DeliveryMedicineDrug Discovery
Paclitaxel (Taxol) is an anticancer drug that induces mitotic arrest via microtubule hyperstabilization but causes side effects due to its hydrophobicity and cellular promiscuity. The targeted cytotoxicity of hydrophilic paclitaxel-conjugated polyamidoamine (PAMAM) dendrimers has been demonstrated in cultured cancer cells. Mechanisms of action responsible for this cytotoxicity are unknown, that is, whether the cytotoxicity is due to paclitaxel stabilization of microtubules, as is whether paclitaxel is released intracellularly from the dendrimer. To determine whether the conjugated paclitaxel can bind microtubules, we used a combination of ensemble and single microtubule imaging techniques in vitro. We demonstrate that these conjugates adversely affect microtubules by (1) promoting the polymerization and stabilization of microtubules in a paclitaxel-dependent manner, and (2) bundling preformed microtubules in a paclitaxel-independent manner, potentially due to protonation of tertiary amines in the dendrimer interior. Our results provide mechanistic insights into the cytotoxicity of paclitaxel-conjugated PAMAM dendrimers and uncover unexpected risks of using such conjugates therapeutically.
| Year | Citations | |
|---|---|---|
Page 1
Page 1